LAPADULA GIUSEPPE

Lapadula, G., Soria, A., Antolini, L., Rugova, A., Colella, E., Sabbatini, F., et al. (2026). HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 81(3) [10.1093/jac/dkag045]. Detail

Russo, A., Giacomelli, A., De Vito, A., Mazzitelli, M., Ceccarelli, M., De Benedittis, S., et al. (2026). Implementing the National Vaccination Plan in people with HIV in Italy: A survey among ICONA centres. HIV MEDICINE, 27(7), 1203-1207 [10.1111/hiv.70241]. Detail

Ripamonti, D., Comi, L., Valenti, D., Cargnelutti, A., Cossu, M., Poloni, A., et al. (2026). Reasons for discontinuation of single-tablet regimen rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF) in the era of 2nd-generation INSTIs. In Abstracts from the 18th Italian Conference on AIDS and Antiviral Research (pp.59-59) [10.1136/sextrans-icar-2026.58]. Detail

Bana, N., Artelli, F., Lapadula, G., Bonfanti, P., Vitiello, P., Abeli, C., et al. (2026). Safety of cabotegravir + rilpivirine long-acting regimen among PLWH with previous HBV exposure: preliminary results of the SCRIBE study. In Abstracts from the 18th Italian Conference on AIDS and Antiviral Research (pp.92-94) [10.1136/sextrans-icar-2026.90]. Detail

Micheli, G., Mondi, A., Roen, A., Taramasso, L., Luchetti, I., Mazzotta, V., et al. (2026). Did the COVID-19 pandemic shift the landscape of late HIV diagnosis?. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 165(April 2026) [10.1016/j.ijid.2026.108437]. Detail